tbuckley/cabot-search huggingface dataset:
Combined immunochemotherapy with reduced dose whole brain radiotherapy (WBRT) for newly diagnosed patients with primary CNS lymphoma (PCNSL)
Authors: F. G. El Kamar, L. M. Deangelis, J. Yahalom, D. D. Correa, B. W. Grant, R. V. Larocca, J. J. Raizer, D. Schiff, L. E. Abrey
Journal: Journal of Clinical Oncology (2004)

1518 Background: High-dose methotrexate based chemotherapy combined with WBRT for patients (pts) with newly diagnosed PCNSL has been shown to improve disease control and overall survival. However, disease recurrence is common and treatment-related neurotoxicity is an increasingly recognized complication. We hypothesized that the addition of Rituximab to Methotrexate, Procarbazine and Vincristine (MPV) might improve overall survival and disease control, similar to that seen with R-CHOP. Also decreasing the dose of WBRT in patients who achieve an initial CR may diminish the risk of treatment related neurotoxicity. This study was designed to determine the safety and efficacy of combined immunochemotherapy followed by reduced dose WBRT. Methods: Seventeen pts (7 men; median KPS 80%) of a planned 30 pts have been enrolled from August 2002 to September 2003. 14 (7M) were treated, 3 were not eligible. Each pt received 500 mg/m2 of rituximab on day 1, MTX 3.5 gm/m2 with VCR 1.4 mg/m2 on day 2. Procarbazine 100 mg/m2/d was given for 7 days. Pts achieving CR after 5–7 cycles received dose reduced WBRT (2340 cGy) while patients with less than a CR received WBRT (4500 cGy). All pts received 2 cycles of ara-c 3gm/m2 after WBRT. All pts are followed with prospective neuropsychological evaluations. CSF + serum levels of rituximab are being assayed in pts with an Ommaya reservoir. Results: Twelve of the 14 treated pts have been assessed for response. Eight (67%) had a CR, 3 (25%) a PR (ORR of 92%) and one (8%) progressed. Eight pts received 2340cGy of WBRT and 3 received 4500 cGy. Three pts were taken off study, 1 for PD and 2 for toxicity (grade 3 nephrotoxicity and death from neutropenic sepsis in one pt each). Other toxicities are reported in table1. Conclusions: The safety and efficacy of R-MPV is comparable to MPV. Further investigation of this regimen in PCNSL is warranted. No significant financial relationships to disclose.
Medical Meetings
Journal: JAMA (1969)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C*1
Authors: M MARTINOTPEIGNOUX
Journal: Hepatology (1995)

The aim of the study was to determine the respective influence of pretreatment serum hepatitis C virus (HCV) RNA levels and HCV genotype on the response to interferon (IFN) alfa in patients with chronic hepatitis C. We retrospectively studied 141 patients with chronic hepatitis C included in two consecutive controlled trials of IFN alfa. A sustained response was observed in 28, a response followed by relapse in 43, and no response in 70 patients. Pretreatment serum HCV RNA quantitation with the branched DNA (bDNA) assay and HCV genotyping with reverse hybridization assay (LiPA) were performed in all patients. Seventy-four percent of the patients had detectable serum HCV RNA (43%, 77% and 84%) in the three groups of patients with sustained response, relapse, and no response, respectively (P = .005). Mean serum HCV RNA level were 1.4 ± 6 x 106, 4.8 ± 6 x 106, and 3.9 ± 5 x 106 genomes/mL in patients with sustained response, response and relapse, and no response, respectively (P < .01). Genotype lb was found in 7%, 47%, and 46% of the patients in the three response groups, respectively. By univariate analysis, age, source, and duration of HCV infection, serum HCV RNA levels, and HCV genotypes were significantly different in the three response groups. By multivariate analysis, the only independent factors associated with sustained response were low serum HCV RNA levels and HCV genotype other than lb. Pretreatment serum HCV RNA levels and HCV genotype are the main and independent factors associated with sustained response to IFN therapy.
ACTION OF MAGNESIUM SULPHATE IN NONSURGICAL DRAINAGE OF THE GALLBLADDER
Journal: JAMA (1922)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Isoniazid toxicity. A prospective study in secondary chemoprophylaxis
Authors: C. B. Byrd
Journal: JAMA (1972)

The toxicity of isoniazid (INH) used as a secondary chemoprophylactic agent was evaluated in 160 adults. Periodic clinical and liver-function evaluations were made during the year of treatment. Sixteen patients (10%) were unable to complete the therapy, 12 of these because of symptomatic reactions. The most frequent symptom complex included fever, myalgias, arthralgias, and nausea or anorexia. Associated elevation of the serum glutamic oxaloacetic transaminase (SGOT) level was frequent, but no patients developed clinical jaundice. The drug was also stopped in four asymptomatic patients because of elevation of the SGOT level to more than 100 units (upper limits of normal 40). The symptomatic reactions and liver-function test abnormalities tended to occur early in therapy. Efforts to detect toxicity should be concentrated in the early weeks of drug administration.
Low vaccination levels of US preschool and school-age children. Retrospective assessments of vaccination coverage, 1991-1992
Authors: E. R. Zell
Journal: JAMA (1994)

<h3>Objective.</h3> —To obtain estimates on (1) the percentage of children who were up-to-date on the recommended childhood vaccination series, (2) the percentage of children who were age-appropriately immunized, and (3) coverage levels by individual vaccines. <h3>Design.</h3> —Vaccination levels were estimated by conducting retrospective immunization coverage surveys of the school health records of children entering kindergarten or first grade in the 1990-1991 or 1991-1992 school year. A multistage cluster survey design was used. <h3>Setting.</h3> —Survey sites were selected from among the 60 largest urban areas in the United States. One small city and one rural area were selected for comparison. <h3>Results.</h3> —By their second birthday, 11% to 58% (median, 44%) of the children were fully vaccinated. Stricter measurement criteria lowered coverage levels further. Completed series levels at school entry were 71% to 96% (median, 87%). <h3>Conclusions.</h3> —Vaccination levels at the second birthday were far below the goal for the year 2000. All health providers need to administer vaccines according to the recommended schedule. (<i>JAMA</i>. 1994;271:833-839)
The burden of responsibility in suicide and homicide
Authors: P. Solomon
Journal: JAMA (1967)

There are 24,000 deaths from suicide annually in the United States and 7,000 from homicide. In addition there are several times as many unsuccessful suicide attempts and attempted homicides, mayhems, and serious assaults and batteries. It is safe to say that a large portion of these involve persons with psychiatric disorders and thus fall under medical jurisdiction. Some of these individuals are overtly psychotic: deluded and hallucinated, or uncontrollably depressed, or assailed by intolerable anxiety, guilt, or hostile feelings. More are acutely neurotic, and their acts may be seen as manipulative gestures, or cries for help, or acting-out maneuvers. A large portion have disordered personalities and faulty character structures, often with alcoholism, narcotic addiction, sexual psychopathy, passive-aggressive disturbance, or emotional immaturity, instability, or inadequacy. Frequent accompaniments are adolescent turmoil, marital discord, school or work problems, chronic or terminal illness, or geriatric disease. Thus the physician has usually been consulted before
Abstract 3598: Phosphoglycerate mutase 1 inhibitor causes metabolic disadvantages in glioblastoma by rescue of FBP1 repression
Authors: Sungmin Lee, Hyunwoo Kim, Hyunkoo Kang, BuHyun Youn
Journal: Cancer Research (2019)

Abstract Radiotherapy is a primary treatment for patients with glioblastoma (GBM). Despite high therapeutic efficacy, the tumor cells that survive after radiotherapy may cause side effects. In this study, we found that fructose 1,6-bisphosphatase 1 (FBP1) which is a rate-limiting enzyme in gluconeogenesis was downregulated upon treatment with ionizing radiation (IR). IR-induced infiltrating GBM has overexpressed Ets1 which was suggested to be a transcriptional repressor of FBP1. Besides, glucose uptake and extracellular acidification rates were increased upon FBP1 downregulation, which indicated an elevated glycolysis level. We found that emodin, an inhibitor of phosphoglycerate mutase 1 derived from natural substances, significantly suppressed the glycolysis rate and the IR-induced GBM aggressiveness in the in vivo orthotopic xenograft mouse models. We propose that the downregulation of FBP1 level reprogrammed the metabolic state of GBM, and thus, FBP1 is a promising therapeutic target regulating GBM metabolism following radiotherapy. Note: This abstract was not presented at the meeting. Citation Format: Sungmin Lee, Hyunwoo Kim, Hyunkoo Kang, BuHyun Youn. Phosphoglycerate mutase 1 inhibitor causes metabolic disadvantages in glioblastoma by rescue of FBP1 repression [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3598.
Intubation of the Trachea in the Critical Care Setting
Authors: Philip D. Lumb
Journal: JAMA (1985)

<h3>To the Editor.—</h3> As anesthesiologists who have been active in the critical care teaching programs at our respective institutions, we have followed the section called CONCEPTS IN EMERGENCY AND CRITICAL CARE with great interest since its first appearance in<i>JAMA</i>. The recent article by Natanson et al,<sup>1</sup>"Intubation of the Trachea in the Critical Care Setting," presents a useful review of the anatomy and the equipment involved in this frequently practiced emergency airway procedure. We believe, however, that the pharmacologic section has been overemphasized while the review of intubation techniques and discussion of approaches to intubation are inadequate. The review of the anatomy and physiology of the airway seems appropriate, as does the section concerning preparation for intubation. The discussion of intubation techniques is unhelpful to the beginner, while the discussion of approaches to intubation in difficult critical care settings may leave dangerous impressions. We find it ironic that
Laxative jaundice.
Journal: BMJ (1972)

Laxative JaundiceIn 1970 over £4m was spent in the United Kingdom on laxatives for self-medication, yet probably few doctors know that these preparations can cause acute and chronic hepatitis.T. B. Reynolds and colleagues' from Los Angeles described the occurrence of an acute hepatitis-like illness in four women taking a laxative preparation, Dialose Plus, in which the active ingredient was oxyphenisatin.The jaundice im- proved in all cases when the laxative was discontinued and
Incorrect Figure Title
Journal: JAMA Internal Medicine (2017)

Meera R. Agar, PhD; Peter G. Lawlor, MB; Stephen Quinn, PhD; Brian Draper, MD; Gideon A. Caplan, MBBS; Debra Rowett, BPharm; Christine Sanderson, MPH; Janet Hardy, MD; Brian Le, MBBS; Simon Eckermann, PhD; Nicola McCaffrey, PhD; Linda Devilee, MBus; Belinda Fazekas, BN; Mark Hill, PhD; David C Currow, PhD
Bioequivalence of Levothyroxine Preparations for Treatment of Hypothyroidism-Reply
Authors: Betty J. Dong
Journal: JAMA (1997)

<h3>In Reply.</h3> —The letter from Dr Spigelman contains several inaccuracies and misconceptions. Treatment guidelines from the leading thyroid societies all were prepared before publication of current data so that current guidelines may need to be updated.<sup>1,2</sup>It should be noted that these treatment guidelines do not actually recommend that retitration is necessary once levothyroxine brands are changed. Previous reports of levothyroxine nonequivalence studied products that were formulated before the adoption of the US Pharmacopeia (USP) guidelines. These guidelines require all manufacturers to monitor and assure the tablet levothyroxine content, thus reducing the potential for tablet subpotency to affect thyroxine equivalence. The high-performance liquid chromatography analysis of the tablet levothyroxine content of our study preparations, despite some variability in our assay, met FDA specifications for proper levothyroxine content. Slight differences in tablet content did not significantly change our results or the analysis by Mayor et al.<sup>3</sup>Clinical interchangeability in patients given
Interferon and ursodeoxycholic acid combined therapy in the treatment of chronic viral C hepatitis: Results from a controlled randomized trial in 80 patients*1
Authors: E BOUCHER
Journal: Hepatology (1995)

Because 70% to 75% of patients with chronic hepatitis C either do not respond to or relapse after interferon (IFN) therapy, and because ursodeoxycholic acid(UDCA) has been shown to reduce aminotransferase levels in patients with chronic hepatitis, we undertook a prospective controlled randomized trial of IFN (group I) versus IFN plus UDCA (group II) in 80 patients with chronic hepatitis C. IFN was administered in both groups for 6 months (3 to 5 million units [mu]three times a week), and in group II UDCA (10 mg/kg/d) was administered with IFN and then alone for 3 additional months. Response to therapy was defined as the normalization of alanine transaminase (ALT) levels. The results showed that 6 months after cessation of IFN, 59% of responders had relapsed in group I but only 27% had relapsed in group II (P = .03). There was no difference between the two groups for the initial (month 6) and the late (months 15 and 18) response rates to IFN. There was no virological effect or significant histological improvement attributable to the addition of UDCA to IFN treatment. In conclusion, the results of this study show that the addition of UDCA to IFN therapy significantly prolongs the period for which serum ALT remain, within the normal range after discontinuation of IFN. Further studies would be required to determine whether UDCA has any potential for long-term amelioration of the histological severity of liver disease caused by hepatitis C virus (HCV) infection, and, therefore, whether it could be advocated as an adjunct to antiviral therapy.
What the pulmonary specialist should know about the new inhalation therapies
Authors: H.M. Janssens, B.L. Laube
Journal: European Respiratory Journal (2012)

generic and reference pMDI should be interchangeable and given the importance of spacer [VHC] use particularly in children, the failure to provide either in vitro or in vivo spacer [VHC] data confirming equivalence would generally preclude regulatory approval of the generic product.''
Wide variations in liver transplantation (LT) policies across Europe for patients with acute-on-chronic liver failure (ACLF) despite excellent post-LT survival: Results of a CLIF/ELITA collaborative study
Authors: Luca Saverio Belli, Christophe Duvoux, Giovanni Perricone, Georges-Philippe Pageaux, Magdalena Meszaros, Thierry Artzner, Baptiste Michard, Sylvie Radenne, Dr. Guichon Céline, Faouzi Saliba, Sophie-Caroline Sacleux, Javier Fernández, Maria Hernandetz, Paolo Angeli, William Bernal, Maria Cristina Morelli, Silvia Martini, Jonel Trebicka, Krzysztof Zieniewicz, Silvio Nadalin, Constantino Fondevila, Wojciech Polak, Christian Toso, Federica Invernizzi, Riccardo Volpes, Claudia Iegri, Marina Berenguer Haym, Paolo Cortesi, Sara Conti, Dev Katarey, Rajiv Jalan, Vicente Arroyo
Journal: Journal of Hepatology (2020)
Transcriptome profiling of liver biopsies before antiviral treatment start can predict HCC development 8.3 years before clinical diagnosis in chronic hepatitis B and C patients
Authors: Stijn Van Hees, Bart Cuypers, Stefan Bourgeois, Kim Kreefft, Dirk Sprengers, Geert Robaeys, Pieter Meysman, Luisa Vonghia, Peter Michielsen, Sven Francque, Robert De Man, Ann Driessen, Andre Boonstra, Kris Laukens, Thomas Vanwolleghem
Journal: Journal of Hepatology (2020)
Pancreatic Society of Great Britain and Ireland. 10th annual meeting. Bristol, 22 November 1985.
Authors: M Lee, T Choi, C Lai, P Wong, H Ngan, J Wong, P Billings, J Leaper, M Shearer, A Mayer, J Mcmahon, A Corfieild, M Cooper, C Williamson
Journal: Gut (1986)

Introduced by V Melikian, Dudley Road Hospital) Accurate early detection of biliary disease in patients presenting with acute pancreatitis can be difficult.Conventional imaging techniques are not entirely reliable, and the value of clinical and biochemical indices has been questioned.We have therefore used endoscopic retrograde cholangiography (ERC) with increasing frequency since 1979 to investigate the biliary tract soon after resolution of acute pancreatitis.During six years ERC was attempted on 150 patients, 134 of whom had suffered their first attack of pancreatitis.Seventy one per cent were examined within three weeks of the acute illness and the success rate was 88%, the major reason for failure being papillary oedema.Biliary calculi were demonstrated in 67 (51%) of the 132 cholangiograms obtained.They were situated in the gall bladder in 44 (33%) and in the bile ducts in 29 (22%).The gall bladder did not fill in 13, always in association with cholelithiasis.No patient with a normal ERC was subsequently found to have biliary disease, although seven of those in whom ERC failed were later shown to have gall stones.Thus overall ERC identified 91% of those with gall stone pancreatitis.Pancreatograms were obtained in 1I1 patients, and 15 were abnormal: eight showed chronic pancreatitis, five ductal obstruction or stenosis, one a small pseudocyst, and one pancreas divisum.The complication rate was low, mild pancreatitis being provoked in two patients (1.3%).We conclude that endoscopic retrograde cholangiopancreatography may be carried out safely soon after resolution of acute pancreatitis, and will identify with certainty those patients who require biliary surgery.Subcutaneous oxygen tension in the prediction of severe acute pancreatitis
Physical Diagnosis
Journal: JAMA (2005)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal